Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive disease. The company said it expects to submit an…
With MS, movement can be one of the greatest teachers
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
Learning to advocate for myself helped me to help others with MS
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
MSBase says keep going with CD20-depletion
Tweet Zanghì A, Spelman T, Fabis-Pedrini M, Carroll WM, Butzkueven H, Kermode AG, Lechner-Scott J, van der Walt A, D’Amico E. Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase. Curr Neuropharmacol. 2026 Mar 24. doi: 10.2174/011570159X448901251228053318. Introduction: Ocrelizumab (OCR), a CD20+ B-cell depleting monoclonal antibody, is a highly effective therapy for Multiple…
In life with MS, we are in this fight together
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
Switching Natalizumab to Biosimilar
Tweet Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO. Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. BMJ Neurol Open. 2026 Mar 18;8(1):e001477. doi: 10.1136/bmjno-2025-001477. Background: In January 2024, all people with…
MS cases double in England over 20 years; life expectancy rises
Multiple sclerosis (MS) has become far more common in England over the past two decades, but people diagnosed more recently are living longer, according to a study led by University College London (UCL). The shift reflects major advances in MS diagnosis and care. But researchers found that social inequalities still increase risks for many, with…
Bittersweet Advocacy
By Stacie Prada I’m proud to advocate on behalf of multiple sclerosis issues, and I aim to normalize discussing human health experiences without shame. If we live long enough, almost all of us will experience big health issues, and learning … Continue reading → Source: blog.mymsaa.org
Multiple sclerosis overview
Multiple sclerosis (MS) is a neurodegenerative disorder caused by the immune system mistakenly attacking the myelin sheath, a protective coating around nerve fibers. This results in inflammation, which further damages the myelin sheath, as well as the nerve cells themselves and the cells that produce myelin. The post Multiple sclerosis overview appeared first on Multiple…
Having relatives with chronic illness fosters a deeper understanding
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….